Case Analysis: T. A. Krishnaswamy vs State of Madras
Case Details
Case name: T. A. Krishnaswamy vs State of Madras
Court: Supreme Court of India
Judges: A.K. Sarkar, J.R. Mudholkar, R.S. Bachawat
Date of decision: 10 December 1965
Citation / citations: 1966 AIR 1022, 1966 SCR (3) 31
Case number / petition number: Criminal Appeal No. 40 of 1964; Criminal Appeal No. 22 of 1961 (Madras High Court)
Proceeding type: Criminal Appeal
Source court or forum: Madras High Court
Source Judgment: Read judgment
Factual and Procedural Background
The appellant, T. A. Krishnaswamy, operated a shop where he manufactured a drug called OKSAL and displayed it for sale. The label on the container claimed that the product contained benzoic acid, salicylic acid, zinc oxide and borboric acid in specified proportions. The prosecution alleged that the drug was misbranded because the actual composition differed from the label.
A Drugs Inspector seized a sample of OKSAL and forwarded it to the Government Analyst with a letter stating that the sample was sent for “test or analysis.” The Government Analyst performed an analysis and issued a triplicate report in Form 13 (Rule 46) stating that the quantities of the four substances were deficient by 15.5 %, 25 %, 25 % and 46.3 % respectively. No protocols of any test were included because the Analyst had performed only an analysis.
The magistrate convicted the appellant under section 18(a)(ii) read with section 27 of the Drugs Act, 1940, imposing a fine of Rs 125 and, in default, one month of rigorous imprisonment. The Sessions Judge set aside the conviction and acquitted the appellant. The State of Madras appealed, and the Madras High Court restored the magistrate’s conviction and sentence. By special leave, the appellant filed Criminal Appeal No. 40 of 1964 before the Supreme Court of India, challenging the High Court’s decision and contending that the Government Analyst’s report was inadmissible because it did not contain the protocols of the tests as required by Rule 46 and Form 13.
Issues, Contentions and Controversy
The Court was called upon to determine whether the Government Analyst’s report was admissible as evidence under the Drugs Act. The specific issue was whether the report complied with the form prescribed by Rule 46 and Form 13, which required that a “report of test or analysis” include the protocols of the tests applied.
The appellant contended that the omission of test protocols rendered the report non‑conforming and therefore inadmissible; he further argued that, without the protocols, the report could not be treated as a “report of the public Analyst” within the meaning of section 25(3) and could not be conclusive evidence.
The State contended that the rule distinguished between a “test” and an “analysis,” and that the requirement to state protocols applied only when a test was performed. Accordingly, the State argued that the Analyst’s report, being an analysis, satisfied the statutory form and was admissible and conclusive under section 25(3) in the absence of any contrary evidence from the accused.
The controversy therefore centered on the interpretation of Rule 46 and Form 13: whether the phrase “protocols of the tests applied” extended to reports of an analysis that did not involve a test, and whether the absence of such protocols invalidated the report.
Statutory Framework and Legal Principles
Section 18(a)(ii) of the Drugs Act, 1940 defined the offence of misbranding when a label made a false statement that was at variance with the actual composition of the drug.
Section 27 of the Drugs Act, 1940 prescribed the punishment for misbranding.
Section 25(3) of the Drugs Act, 1940 provided that the report of the public Analyst shall be evidence of the facts stated therein and such evidence shall be conclusive unless the accused adduced evidence to the contrary in the manner laid down.
Rule 46 of the rules made under the Drugs Act required the Government Analyst to forward a report in triplicate on Form 13, together with full protocols of the tests applied, after the test or analysis had been completed.
Form 13 (Head 7) prescribed that the report should contain “Results of test or analysis with protocols of tests applied.”
The Court articulated a two‑fold test for admissibility: (1) whether the report complied with the prescribed form under Rule 46 and Form 13; and (2) whether, once admitted, the report was conclusive evidence under section 25(3) absent any contrary evidence from the accused.
The binding principle that emerged was that a Government Analyst’s report of analysis, even without the inclusion of test protocols, satisfied the statutory form and was admissible as conclusive evidence under section 25(3), provided the accused did not produce contrary evidence.
Court’s Reasoning and Application of Law
The Court examined the language of Rule 46 and Form 13 and observed that the terms “test” and “analysis” were used separately. It held that the requirement to state “protocols of the tests applied” applied only when the report concerned a test. Because the Analyst had performed an analysis and not a test, the omission of protocols did not render the report non‑conforming.
Applying section 25(3), the Court noted that the appellant had produced no evidence to rebut the Analyst’s findings. Consequently, the report was deemed conclusive evidence of the quantities of the ingredients present in the drug.
In applying section 18(a)(ii) read with section 27, the Court found that the label’s false statement regarding the proportions of benzoic acid, salicylic acid, zinc oxide and boric acid rendered the drug misbranded. The factual matrix—deficiencies of 15.5 %, 25 %, 25 % and 46.3 % respectively—supported the conviction.
The Court distinguished the earlier decision in Rai Kishan v. State of Uttar Pradesh on the ground that that case involved a report of a test, whereas the present case involved a report of an analysis. Accordingly, the earlier precedent did not control the present issue.
Final Relief and Conclusion
The Supreme Court refused the appellant’s relief. It dismissed the appeal, upheld the conviction and sentence originally imposed by the magistrate and restored by the Madras High Court, and affirmed that the Government Analyst’s report was admissible and conclusive evidence under section 25(3) of the Drugs Act.